Atrial fibrillation and the use of oral bisphosphonates
Michael Pazianas1, Cyrus Cooper1,2, Yiting Wang3, Jeff L Lange4, R Graham G Russell1,51The Botnar Research Centre, Oxford University, Oxford, UK; 2MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK; 3Warner Chilcott Pharmaceuticals, USA; 4Procter & Gamble Company, C...
Saved in:
Main Authors: | Michael Pazianas (Author), Cyrus Cooper (Author), Yiting Wang (Author), et al (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
by: Michael Pazianas, et al.
Published: (2010) -
Eliminating the need for fasting with oral administration of bisphosphonates
by: Pazianas M, et al.
Published: (2013) -
Inflammatory cytokines and atrial fibrillation: current and prospective views
by: Hadi AR Hadi, et al.
Published: (2010) -
The use of oral anticoagulants in patients with atrial fibrillation: cohort study data
by: O. V. Gaisenok, et al.
Published: (2016) -
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
by: Turpie AGG
Published: (2014)